Literature DB >> 28530669

Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.

M Mohty1,2, P Drillat3, J-M Grouin4, F Bijou5, N Milpied6, C Chabannon7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28530669     DOI： 10.1038/bmt.2017.80

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

Review 1.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

Review 2.  The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.

Authors:  M Mohty; R F Duarte; S Croockewit; K Hübel; G Kvalheim; N Russell
Journal:  Leukemia       Date:  2011-01       Impact factor: 11.528

3.  A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.

Authors:  S Abhyankar; S DeJarnette; O Aljitawi; S Ganguly; D Merkel; J McGuirk
Journal:  Bone Marrow Transplant       Date:  2011-07-04       Impact factor: 5.483

4.  A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.

Authors:  Christian Chabannon; Fontanet Bijou; Jean-Michel Miclea; Noel Milpied; Jean-Marie Grouin; Mohamad Mohty
Journal:  Transfusion       Date:  2015-05-13       Impact factor: 3.157

5.  Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.

Authors:  Nina Worel; Gerhard Fritsch; Hermine Agis; Alexandra Böhm; Georg Engelich; Gerda C Leitner; Klaus Geissler; Karoline Gleixner; Peter Kalhs; Veronika Buxhofer-Ausch; Felix Keil; Gerhard Kopetzky; Viktor Mayr; Werner Rabitsch; Regina Reisner; Konrad Rosskopf; Reinhard Ruckser; Claudia Zoghlami; Niklas Zojer; Hildegard T Greinix
Journal:  J Clin Apher       Date:  2016-08-31       Impact factor: 2.821

6.  A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

Authors:  Amanda Cashen; Sandra Lopez; Feng Gao; Gary Calandra; Ron MacFarland; Karin Badel; John DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

7.  Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.

Authors:  I Sánchez-Ortega; S Querol; M Encuentra; S Ortega; A Serra; J M Sanchez-Villegas; J R Grifols; M M Pujol-Balaguer; M Pujol-Bosch; J M Martí; T Garcia-Cerecedo; P Barba; J M Sancho; A Esquirol; J Sierra; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

8.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  8 in total
  1 in total

Review 1.  Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.

Authors:  Jian Chen; Hillard M Lazarus; Parastoo B Dahi; Scott Avecilla; Sergio A Giralt
Journal:  Blood Rev       Date:  2020-10-31       Impact factor: 10.626
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.